Add-On Antihistamines Offer Little Benefit in Atopic Dermatitis

Key Takeaways

• Across 47 randomized trials involving 6,230 patients with mainly moderate to severe AD, add-on antihistamines were not associated with important improvements in core eczema outcomes.
• Second-generation H1 antihistamines showed statistically detectable reductions in disease and itch severity, but those changes did not reach patient-important thresholds.
• First-generation H1 antihistamines did not differ from placebo for disease severity or itch severity.
• Limited, low-certainty evidence suggested that sleep disturbance and AD exacerbations may not importantly differ from placebo, while one small quality-of-life study found no significant difference.
• First-generation H1 antihistamines probably increased cognitive impairment, while serious adverse events did not increase with first- or second-generation H1 antihistamines.

Oral antihistamines have long been added to eczema care when itch or nighttime symptoms dominate, but whether add-on therapy changes core atopic dermatitis (AD) outcomes has remained uncertain. The familiar split between first- and second-generation agents has also left open whether any benefit reflects sedation or a meaningful change in disease activity. That unresolved clinical question set the stage for the evidence Chu and colleagues assembled.

In a BMJ systematic review and network meta-analysis of antihistamines in atopic dermatitis, Chu and colleagues searched five databases through May 5, 2025, and identified 47 randomized controlled trials involving 6,230 patients with mainly moderate to severe AD. Investigators evaluated add-on oral H1 antihistamines, H2 blockers, mast cell stabilizers, or combinations against placebo, with or without background topical treatment, and assessed disease severity, itch severity, sleep disturbance, exacerbations, quality of life, and harms. The analysis was designed to show what adjunctive antihistamine therapy added beyond background eczema treatment.

Across 27 studies (n=3,541), second-generation H1 antihistamines lowered AD severity versus placebo by a mean difference of -1.87 (95% credible interval [CrI], -3.47 to -0.27), but that change remained below the minimal important difference threshold of 8.2. Across 27 trials (n=2,667), they also lowered itch severity by a mean difference of -0.89 (95% CrI, -1.41 to -0.37), which stayed below the minimal important difference threshold of 3. First-generation H1 antihistamines did not differ from placebo for either outcome.

Limited, low-certainty evidence suggested that sleep disturbance and AD exacerbations may not importantly differ from placebo, while one small quality-of-life study found no significant difference, and no first-generation H1 antihistamine trials contributed to the sleep-disturbance outcome set. The clearest safety contrast was that first-generation H1 antihistamines probably increased cognitive impairment, with a risk difference of 66 more per 1,000 versus placebo (95% CrI, 0 to 231). Treatment discontinuation due to adverse events may also have been higher with first-generation agents, whereas serious adverse events did not increase with first- or second-generation H1 antihistamines.

The findings mainly distinguished statistically detectable score changes from changes large enough to meet patient-important thresholds, and the second-generation signal met only the former standard in the reported outcomes. Sleep disturbance and quality-of-life estimates were especially tentative because those outcomes rested on limited evidence.

Chu and colleagues reported little patient-important benefit from add-on antihistamines for core AD outcomes. Any measurable efficacy signal was confined to second-generation H1 agents, whereas first-generation agents showed no corresponding improvement in disease or itch outcomes. In the reported data, cognitive impairment with first-generation antihistamines was the clearest safety concern.

Clinician Questions

Which patients with atopic dermatitis were represented in the antihistamine review?

The review mainly represented patients with moderate to severe atopic dermatitis receiving add-on therapy versus placebo, with or without background topical treatment, so the findings are most directly bounded to that treatment setting. The median reported mean age was 20 years and the median proportion female was 52%.

Were first-generation H1 antihistamines evaluated for sleep disturbance in atopic dermatitis?

Sleep-disturbance evidence came from four trials of investigated antihistamines other than first-generation agents, so first-generation H1 antihistamines were not directly represented in that outcome set. Within that limited evidence base, investigators did not identify an important difference from placebo.

How much evidence supported quality-of-life outcomes with add-on antihistamines in atopic dermatitis?

AD-related quality of life was informed by one levocetirizine-versus-placebo study with 40 patients, which did not show a significant difference. That made the quality-of-life evidence especially limited compared with the disease-severity and itch analyses.